226 related articles for article (PubMed ID: 24587223)
1. De novo peptide design and experimental validation of histone methyltransferase inhibitors.
Smadbeck J; Peterson MB; Zee BM; Garapaty S; Mago A; Lee C; Giannis A; Trojer P; Garcia BA; Floudas CA
PLoS One; 2014; 9(2):e90095. PubMed ID: 24587223
[TBL] [Abstract][Full Text] [Related]
2. De novo peptide design and experimental validation of histone methyltransferase inhibitors.
Smadbeck J; Peterson MB; Zee BM; Garapaty S; Mago A; Lee C; Giannis A; Trojer P; Garcia BA; Floudas CA
PLoS One; 2014; 9(4):e95535. PubMed ID: 24740276
[TBL] [Abstract][Full Text] [Related]
3. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
McCabe MT; Graves AP; Ganji G; Diaz E; Halsey WS; Jiang Y; Smitheman KN; Ott HM; Pappalardi MB; Allen KE; Chen SB; Della Pietra A; Dul E; Hughes AM; Gilbert SA; Thrall SH; Tummino PJ; Kruger RG; Brandt M; Schwartz B; Creasy CL
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2989-94. PubMed ID: 22323599
[TBL] [Abstract][Full Text] [Related]
4. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
5. Substrate preferences of the EZH2 histone methyltransferase complex.
Martin C; Cao R; Zhang Y
J Biol Chem; 2006 Mar; 281(13):8365-70. PubMed ID: 16431907
[TBL] [Abstract][Full Text] [Related]
6. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
7. Quantification of histone H3 Lys27 trimethylation (H3K27me3) by high-throughput microscopy enables cellular large-scale screening for small-molecule EZH2 inhibitors.
Luense S; Denner P; Fernández-Montalván A; Hartung I; Husemann M; Stresemann C; Prechtl S
J Biomol Screen; 2015 Feb; 20(2):190-201. PubMed ID: 25409661
[TBL] [Abstract][Full Text] [Related]
8. Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation.
Rush M; Appanah R; Lee S; Lam LL; Goyal P; Lorincz MC
Epigenetics; 2009 Aug; 4(6):404-14. PubMed ID: 19717977
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
10. Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys²⁷ methylation by human polycomb repressive complex 2 and vSET.
Swalm BM; Hallenbeck KK; Majer CR; Jin L; Scott MP; Moyer MP; Copeland RA; Wigle TJ
Biochem J; 2013 Jul; 453(2):241-7. PubMed ID: 23679895
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens.
Diaz E; Machutta CA; Chen S; Jiang Y; Nixon C; Hofmann G; Key D; Sweitzer S; Patel M; Wu Z; Creasy CL; Kruger RG; LaFrance L; Verma SK; Pappalardi MB; Le B; Van Aller GS; McCabe MT; Tummino PJ; Pope AJ; Thrall SH; Schwartz B; Brandt M
J Biomol Screen; 2012 Dec; 17(10):1279-92. PubMed ID: 22904200
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.
Dudakovic A; Camilleri ET; Xu F; Riester SM; McGee-Lawrence ME; Bradley EW; Paradise CR; Lewallen EA; Thaler R; Deyle DR; Larson AN; Lewallen DG; Dietz AB; Stein GS; Montecino MA; Westendorf JJ; van Wijnen AJ
J Biol Chem; 2015 Nov; 290(46):27604-17. PubMed ID: 26424790
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Chen H; Tu SW; Hsieh JT
J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
[TBL] [Abstract][Full Text] [Related]
15. Role of histone H3 lysine 27 methylation in Polycomb-group silencing.
Cao R; Wang L; Wang H; Xia L; Erdjument-Bromage H; Tempst P; Jones RS; Zhang Y
Science; 2002 Nov; 298(5595):1039-43. PubMed ID: 12351676
[TBL] [Abstract][Full Text] [Related]
16. Structural insights into binding of small molecule inhibitors to Enhancer of Zeste Homolog 2.
Kalinić M; Zloh M; Erić S
J Comput Aided Mol Des; 2014 Nov; 28(11):1109-28. PubMed ID: 25139678
[TBL] [Abstract][Full Text] [Related]
17. Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3.
Kuzmichev A; Jenuwein T; Tempst P; Reinberg D
Mol Cell; 2004 Apr; 14(2):183-93. PubMed ID: 15099518
[TBL] [Abstract][Full Text] [Related]
18. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
[TBL] [Abstract][Full Text] [Related]
19. Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells.
Valente S; Lepore I; Dell'Aversana C; Tardugno M; Castellano S; Sbardella G; Tomassi S; Di Maro S; Novellino E; Di Santo R; Costi R; Altucci L; Mai A
Biochimie; 2012 Nov; 94(11):2308-13. PubMed ID: 22709867
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
